SCHEMBL12440445

SCHEMBL12440445

CCOCC(=O)NC1CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.54
NPSR1 Q6W5P4 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.47
SMYD3 Q9H7B4 1/20 0.45
LMNA P02545 1/20 0.45
ATF4 P18848 1/20 0.45
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.43
KMT2A Q03164 1/20 0.43
HPGD P15428 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ATM Q13315 1/20 0.42
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
DRD2 P14416 1/20 0.41
HTR2A P28223 1/20 0.41
DRD3 P35462 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17730249 0.93 USP2 (0.49) USP2NPSR1L3MBTL1SMYD3LMNA
SCHEMBL17730252 0.93 USP2 (0.49) USP2NPSR1L3MBTL1SMYD3LMNA
SCHEMBL12438989 0.92 NPSR1 (0.59) USP2NPSR1L3MBTL1ALDH1A1TSHR
SCHEMBL6003218 0.92 NPSR1 (0.65) USP2NPSR1L3MBTL1ALDH1A1TSHR
SCHEMBL14309155 0.90 NPSR1 (0.68) USP2NPSR1L3MBTL1ALDH1A1TSHR
SCHEMBL18330454 0.86 USP2 (0.47) USP2NPSR1L3MBTL1LMNAALDH1A1
SCHEMBL18330481 0.84 L3MBTL1 (0.49) USP2NPSR1L3MBTL1MEN1POLB
SCHEMBL17741000 0.82 NPSR1 (0.62) NPSR1ALDH1A1TSHRHSD17B10MEN1
SCHEMBL18330504 0.82 EPHX2 (0.57) ATF4
SCHEMBL13521530 0.81 USP2 (0.46) USP2NPSR1L3MBTL1ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190271-A1 2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents RIGEL PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
US-20080021020-A1 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents RIGEL PHARMACEUTICALS, INC. (US) 2008-01-24 US disclosed
US-20080009484-A1 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents RIGEL PHARMACEUTICALS, INC. (US) 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009484-A1 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents MKI67, TYMP, PCNA USP2 3853/4885NPSR1 4094/4885L3MBTL1 2445/4885
US-20080021020-A1 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents MKI67, TYMP, PCNA USP2 3853/4885NPSR1 4094/4885L3MBTL1 2445/4885
US-20110190271-A1 2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents MKI67, TYMP, PCNA USP2 3853/4885NPSR1 4094/4885L3MBTL1 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.